Our advisors


The members of Euveda's Business Advisory Board have extensive entrepreneurial backgrounds in biotechnology, and are actively involved in shaping the strategy to successfully take the company's innovations to market.


Joel Braunstein, MD, MBA

Dr. Braunstein is a Co-Founder and CEO of LifeTech Research, a life sciences investment research firm. In addition to shaping the vision and strategy of LifeTech Research and its affiliate companies, he provides analytics in the areas of clinical trial design and methods, outcomes research, and healthcare policy and economics. He has launched numerous life sciences companies and is a board member of C2N Diagnostics, a rapidly emerging Alzheimer’s (and other neurodegenerative disorder) diagnostics and biomarker company; Centegen, a therapeutics company developing novel agents against drug-resistant staphylococci; NexGen Medical Systems and Correx, device companies each developing transformative minimally-invasive surgical and vascular interventional devices; and Tivorsan Pharmaceuticals, a biologics company developing a recombinant protein for a serious genetic disorder.

Dr. Braunstein received his MD with highest distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women's Hospital, Harvard Medical School until 1999, and as a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with management focus in 2004 and maintained an Assistant Professor cardiology faculty position, both at Johns Hopkins University. He remains an advisor to the Johns Hopkins Carey School of Business, and is a Distinguished Alumnus of the University.




David Fink, PhD

Dr. Fink is the Director of Entrepreneurial Services at the UMBC bwtech Life Science and Technology Incubator. Dr. Fink also teaches entrepreneurship through the very successful ACTiVATE program (to encourage women entrepreneurs to launch technology companies) and the INNoVATE program (to train postdocs and business professionals to launch companies), which are funded by the NSF Partnerships for Innovation Program.

Dr. Fink's career in biotechnology and biomedical product development spans over 30 years as a researcher, research manager, consultant, entrepreneur and officer of several start-up biotech companies. Dr. Fink was trained in chemical engineering at the Universities of Cincinnati and Michigan and was a post-doctoral fellow at Purdue University. He then joined Battelle Memorial Institute in Columbus, OH where he conducted and managed research on over 100 projects over a 12-year period. In 1988 he founded and served as President of CollaTek, Inc., in collaboration with Gattefosse SA of Lyon, France, to develop and commercialize technology licensed from Battelle for manufacturing collagen-based medical implants. Dr. Fink became the second employee of Osiris Therapeutics at the time it was founded in 1993. Osiris is a Baltimore tissue regeneration company with a platform technology based on adult stem cells. In 1997, Dr. Fink became Vice President for International Technology Development and was responsible for planning and coordination of all international programs and collaborations conducted by Osiris, including a major corporate partnership with Novartis. Dr. Fink joined Chondros, a start-up cell therapy company in Baltimore, as its first employee in 2001, and he continued as its President and COO until November 2003.




Gary Brooker, PhD

Dr. Brooker is a Research Professor in the Biomedical Engineering department at the Johns Hopkins University and the Director of the Microscopy center at JHU’s Montgomery County campus. He has published numerous peer-reviewed publications and has been granted more than a dozen patents.

Dr. Brooker is also currently the Founder and CEO of CellOptic, which is developing innovative 3D imaging solutions for life science and engineering applications. Previously, Dr. Brooker was the Founder and CSO of Atto Biosciences, a leader in the high content screening instrumentation space, which was acquired by Becton Dickinson in 2004.